about
Changes in management and outcomes for children and adolescents with type 1 diabetes over the last 50 years.A Fixed Ratio Combination of Insulin Degludec and Liraglutide (IDegLira) Reduces Glycemic Fluctuation and Brings More Patients with Type 2 Diabetes Within Blood Glucose Target RangesInsulin analogs--is there a compelling case to use them? No!Visit-to-visit variability of fasting plasma glucose as predictor of ischemic stroke: competing risk analysis in a national cohort of Taiwan Diabetes Study.Cardiovascular effects of dapagliflozin in patients with type 2 diabetes and different risk categories: a meta-analysis.Oscillating glucose induces microRNA-185 and impairs an efficient antioxidant response in human endothelial cells.Feasibility of overnight closed-loop therapy in young children with type 1 diabetes aged 3-6 years: comparison between diluted and standard insulin strength.Dapagliflozin combination therapy in type 2 diabetes mellitus.The Comprehensive Glucose Pentagon: A Glucose-Centric Composite Metric for Assessing Glycemic Control in Persons With Diabetes.Glucose variability, HbA1c and microvascular complications.50 years forward: mechanisms of hyperglycaemia-driven diabetic complications.Vascular complications in diabetes: old messages, new thoughts.Variability in HbA1c, blood pressure, lipid parameters and serum uric acid, and risk of development of chronic kidney disease in type 2 diabetes.Carotid Intima-Media Thickness and Visit-to-Visit HbA1c Variability Predict Progression of Chronic Kidney Disease in Type 2 Diabetic Patients with Preserved Kidney Function.Ten-year hemoglobin A1c trajectories and outcomes in type 2 diabetes mellitus: The Diabetes & Aging Study.Direct association of visit-to-visit HbA1c variation with annual decline in estimated glomerular filtration rate in patients with type 2 diabetesChallenges in Delivering Smaller Doses of Insulin.Novel antidiabetic nutrients identified by in vivo screening for gastric secretion and emptying regulation in rats.A unique plasma microRNA profile defines type 2 diabetes progression.Day-to-day fasting glycaemic variability in DEVOTE: associations with severe hypoglycaemia and cardiovascular outcomes (DEVOTE 2).Dapagliflozin improves treatment satisfaction in overweight patients with type 2 diabetes mellitus: a patient reported outcome study (PRO study).
P2860
Q30369998-F0804E95-0539-4AEC-B692-8C809EF4C470Q33588613-7C5D2878-CB5D-4FA4-BA25-00D15D4C5543Q33646601-485A34A2-D15C-4682-9A19-99059544FA29Q34278597-963810B9-1AF7-419E-9F81-72FBF1B0E2EAQ36599869-94D8DF7B-F102-4C2A-828E-3DD24B9083DFQ36855706-909AEB31-57E1-472A-9008-3AF481F69DB1Q38419059-70AA7F5D-D510-4FB3-A0D7-5F88AAD9981AQ38634051-0AB9AB02-38A5-4B8D-856E-D1DB5393F0BBQ38658269-A1092BFF-C0F9-44C0-94DB-560A061F5471Q38774291-007920C6-1C1F-4411-BA38-CC627A3FA0F0Q39014705-14948FF8-904B-49BD-8ADA-9F35DB1CDB84Q39446720-43DB2EA5-5C1D-41E3-99C5-FBC426FAE3BAQ40232094-981B6F6F-9AEE-430B-B931-88365DED60BCQ40538908-011F7B7F-27D7-4A7D-808E-2E814A275DD0Q40630010-2FE9E49B-BB51-43B3-B291-ABD4D1D6F991Q41846923-4FEDE29A-4802-4734-9FA8-0D06868FB6F4Q41866230-1F1659B5-A6FD-43E2-93A3-258C7C350BBDQ43917600-E073EEBE-17B0-4282-BCF0-C73AE3C73B6FQ48188097-38628F40-5EA8-4129-9FD3-BBBA922C7328Q50075924-3B78C350-BEB3-4B80-A259-2A0F0A2FA964Q51744128-A527AFB5-6EE4-4E99-A2B2-84102ED8D760
P2860
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Glycemic variability: both sides of the story.
@en
type
label
Glycemic variability: both sides of the story.
@en
prefLabel
Glycemic variability: both sides of the story.
@en
P2860
P356
P1433
P1476
Glycemic variability: both sides of the story.
@en
P2093
Eric S Kilpatrick
P2860
P304
P356
10.2337/DCS13-2030
P407
P478
36 Suppl 2
P577
2013-08-01T00:00:00Z